0000000000274255

AUTHOR

Flavio Caprioli

0000-0002-8077-8175

showing 17 related works from this author

The Italian clinical experience with adalimumab in Crohn's disease: Eleven clinical cases

2010

Crohn's diseasemedicine.medical_specialtyHepatologybusiness.industryInternal medicineGastroenterologymedicinePhysical therapyAdalimumabmedicine.diseasebusinessmedicine.drugDigestive and Liver Disease Supplements
researchProduct

Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study

2019

Abstract Background Few data exist regarding the effectiveness of ustekinumab in inflammatory bowel disease (IBD) patients treated for concomitant psoriasis or psoriatic arthritis. Aims to describe the outcomes of IBD patients who received subcutaneous ustekinumab through a dermatological or rheumatological prescription. Methods This multicenter, retrospective study included all IBD patients who were started on ustekinumab for concomitant active psoriasis/ psoriatic arthritis, irrespective of IBD activity. The primary endpoint was overall ustekinumab persistence, defined as the maintenance of therapy because of sustained clinical benefit for IBD. Results Seventy patients (64 Crohn’s disease…

MaleCrohn’s diseaseSettore MED/16 - REUMATOLOGIAPsoriaticCrohn's disease; Psoriasis; Psoriatic arthritis; Ulcerative colitis; Ustekinumab; Hepatology; GastroenterologyInflammatory bowel disease0302 clinical medicineClinical endpointCrohn's disease Psoriasis Psoriatic arthritis Ulcerative colitis UstekinumabCrohn's diseaseSettore MED/12 - GastroenterologiaGastroenterologyMiddle AgedUlcerative colitisCrohn's diseaseTreatment OutcomeItaly030220 oncology & carcinogenesisPsoriatic arthritis030211 gastroenterology & hepatologyFemaleUstekinumabmedicine.drugAdultmedicine.medical_specialty03 medical and health sciencesPsoriatic arthritisCrohn's disease; Psoriasis; Psoriatic arthritis; Ulcerative colitis; Ustekinumab; Adult; Aged; Arthritis Psoriatic; Dermatologic Agents; Female; Humans; Inflammatory Bowel Diseases; Italy; Logistic Models; Male; Middle Aged; Psoriasis; Retrospective Studies; Treatment Outcome; Ustekinumab; Young AdultYoung AdultInternal medicinePsoriasisUstekinumabmedicineHumansPsoriasisAgedRetrospective StudiesHepatologybusiness.industryArthritisArthritis Psoriaticmedicine.diseaseInflammatory Bowel Diseasesdigestive system diseasesCrohn’s disease; Psoriasis; Psoriatic arthritis; Ulcerative colitis; UstekinumabLogistic ModelsUlcerative colitisConcomitantDermatologic Agentsbusiness
researchProduct

Mongersen, an oral SMAD7 antisense oligonucleotide, and crohn's disease

2015

Crohn's disease-related inflammation is characterized by reduced activity of the immunosuppressive cytokine transforming growth factor β1 (TGF-β1) due to high levels of SMAD7, an inhibitor of TGF-β1 signaling. Preclinical studies and a phase 1 study have shown that an oral SMAD7 antisense oligonucleotide, mongersen, targets ileal and colonic SMAD7.In a double-blind, placebo-controlled, phase 2 trial, we evaluated the efficacy of mongersen for the treatment of persons with active Crohn's disease. Patients were randomly assigned to receive 10, 40, or 160 mg of mongersen or placebo per day for 2 weeks. The primary outcomes were clinical remission at day 15, defined as a Crohn's Disease Activit…

MaleSMAD7 antisense oligonucleotidemedicine.medical_treatmentOligonucleotidesPharmacologyPLACEBO-CONTROLLED TRIALTHERAPYGastroenterologylaw.inventionACTIVATIONImmunosuppressive AgentGlucocorticoidRandomized controlled trialCrohn DiseaselawOligonucleotideMedicineYoung adultCrohn's diseaseSettore MED/12 - GastroenterologiabiologyINDUCTIONMedicine (all)Remission InductionGeneral MedicineMiddle AgedCrohn's diseaseCytokineC-Reactive ProteinCombinationDrug Therapy CombinationFemaleDrugImmunosuppressive AgentsCOLITISHumanAdultmedicine.medical_specialtyAdolescentINFLAMMATORY-BOWEL-DISEASE PLACEBO-CONTROLLED TRIAL NECROSIS-FACTOR-ALPHA TGF-BETA-1-MEDIATED SUPPRESSION COLITIS INDUCTION ACTIVATION EFFICACY THERAPY MICEPlaceboSmad7 ProteinDose-Response RelationshipYoung AdultPharmacotherapyDouble-Blind MethodDrug TherapyInternal medicineHumansAntisenseGlucocorticoidsAgedDose-Response Relationship Drugbusiness.industryC-reactive proteinNECROSIS-FACTOR-ALPHAOligonucleotides AntisenseTGF-BETA-1-MEDIATED SUPPRESSIONEFFICACYmedicine.diseaseClinical trialMICEbiology.proteinbusinessAdolescent; Adult; Aged; C-Reactive Protein; Crohn Disease; Dose-Response Relationship Drug; Double-Blind Method; Drug Therapy Combination; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Male; Middle Aged; Oligonucleotides; Oligonucleotides Antisense; Remission Induction; Smad7 Protein; Young Adult; Medicine (all)INFLAMMATORY-BOWEL-DISEASE
researchProduct

Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey

2020

Telemedicinemedicine.medical_specialtytelemedicine; COVID-19; inflammatory bowel disease; Aftercare; Betacoronavirus; Hospitalization; Humans; Infection Control; Italy; Mass Screening; Organizational Innovation; Remote Consultation; Surveys and Questionnaires; Coronavirus Infections; Hospital Units; Inflammatory Bowel Diseases; Pandemics; Pneumonia Viral; TelemedicinePneumonia ViralAftercareInflammatory bowel diseaselaw.inventionSettore MED/12Betacoronaviruslawinflammatory bowel diseaseSurveys and QuestionnairesmedicineInfection controlImmunology and AllergyHumansMass ScreeningViralLetters to the EditorPandemicsMass screeningAcademicSubjects/MED00260Remote ConsultationCOVID-19; inflammatory bowel disease; telemedicine; Aftercare; Betacoronavirus; COVID-19; Hospitalization; Humans; Infection Control; Italy; Mass Screening; Organizational Innovation; Remote Consultation; SARS-CoV-2; Surveys and Questionnaires; Coronavirus Infections; Hospital Units; Inflammatory Bowel Diseases; Pandemics; Pneumonia Viral; TelemedicineInfection Controlbusiness.industrySARS-CoV-2Remote ConsultationGastroenterologyCOVID-19PneumoniaBiological productmedicine.diseaseInflammatory Bowel DiseasesIntensive care unitOrganizational InnovationTelemedicineHospitalizationDiarrheaItalyEmergency medicinemedicine.symptomtelemedicine; COVID-19; inflammatory bowel diseasebusinessCoronavirus InfectionsHospital UnitsInflammatory Bowel Diseases
researchProduct

SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 Milan outbreak

2020

Objectives: The Milan metropolitan area in Northern Italy was among the most severely hit by the SARS-CoV-2 outbreak. The epidemiological trends of mild COVID-19 are however still unknown. The aim of this study was to examine the seroprevalence of SARS-CoV-2 infection in healthy asymptomatic adults, the risk factors, and laboratory correlates. Design: We conducted a cross-sectional study during the outbreak. Presence of anti-SARS-CoV-2 IgM/IgG antibodies against the Nucleocapsid protein was assessed by a lateral flow immunoassay. Setting: Blood center at a leading academic hospital serving as COVID-19 referral center. Participants: We considered a random sample of blood donors since the sta…

0303 health sciencesmedicine.medical_specialtybiologymedicine.diagnostic_testbusiness.industryOutbreakLogistic regressionAsymptomatic3. Good health03 medical and health sciences0302 clinical medicineInternal medicineEpidemiologybiology.proteinmedicineSeroprevalence030212 general & internal medicineAntibodymedicine.symptomSeroconversionLipid profilebusiness030304 developmental biology
researchProduct

Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standard…

2020

BACKGROUND AND AIMS: Restructuring activities have been necessary during the lockdown phase of the coronavirus disease 2019 (COVID-19) pandemic. Few data are available on the post-lockdown phase in terms of health-care procedures in inflammatory bowel disease (IBD) care, and no data are available specifically from IBD units. We aimed to investigate how IBD management was restructured during the lockdown phase, the impact of the restructuring on standards of care and how Italian IBD units have managed post-lockdown activities. METHODS: A web-based online survey was conducted in two phases (April and June 2020) among the Italian Group for IBD affiliated units within the entire country. We inv…

Crohn’s diseasemedicine.medical_specialtystandards of careCOVID-19; Crohn’s disease; Inflammatory bowel disease; standards of care; therapy; ulcerative colitis; COVID-19; Critical Pathways; Disease Management; Humans; Inflammatory Bowel Diseases; Italy; Pandemics; Public Health Surveillance; Quality of Life; Surveys and Questionnaires; Standard of CareInflammatory bowel diseaseInflammatory bowel disease03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Public health surveillanceAmbulatory careSurveys and QuestionnairesPandemicmedicineHumansPublic Health SurveillanceDisease management (health)Intensive care medicinePandemicsulcerative colitisCrohn's diseasetherapybusiness.industryGastroenterologyDisease ManagementCOVID-19Standard of Caremedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisOncologyItalyCOVID-19; Crohn’s disease; Inflammatory bowel disease; standards of care; therapy; ulcerative colitis030220 oncology & carcinogenesisCritical PathwaysQuality of Life030211 gastroenterology & hepatologybusiness
researchProduct

PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instability

2020

Small bowel adenocarcinomas (SBAs) are often associated with poor prognosis and have limited therapeutic options. Programmed cell death protein-1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway blockade is an effective treatment in many microsatellite instability-high (MSI-H) solid tumors. We aimed at investigating PD-L1 and PD-1 expression in non-hereditary, non-ampullary SBAs, associated with celiac disease (CeD), Crohn’s disease (CrD), or sporadic, recruited through the Small Bowel Cancer Italian Consortium. We assessed PD-L1 and PD-1 by immunohistochemistry in a series of 121 surgically resected SBAs, including 34 CeD-SBAs, 49 CrD-SBAs, and 38 sporadic SBAs. PD-L1 and PD-1 express…

0301 basic medicineMalePD-L1 - small bowel adenocarcinoma - tumor-infiltrating lymphocytes - microsatellite instabilityPathologyBLOCKADEColorectal cancerLymphocyteSmall bowel adenocarcinomaGastroenterologyB7-H1 AntigenSettore MED/120302 clinical medicineCrohn DiseaseIntestine Smallsmall bowel adenocarcinomaSmall bowel adenocarcinomasMEDULLARY CARCINOMA; MORPHOLOGY; EXPRESSION; BLOCKADE; CANCERbiologymicrosatelliteinstabilityMiddle AgedCANCERmedicine.anatomical_structureMedullary carcinomatumor infiltrating lymphocytes030220 oncology & carcinogenesistumor-infiltrating lymphocytesAdenocarcinomaFemaleMicrosatellite InstabilityPD-L1Adultmedicine.medical_specialtysmall bowel adenocarcinoma tumor-infiltrating lymphocytes microsatelliteinstabilitySettore MED/08 - Anatomia PatologicaAdenocarcinomaMEDULLARY CARCINOMAPD-L1 small bowel adenocarcinomaNOPathology and Forensic Medicine03 medical and health sciencesLymphocytes Tumor-InfiltratingInternal medicinePD-L1expressionIntestinal NeoplasmsBiomarkers TumormedicineHumansPD-L1; small bowel adenocarcinoma; tumor infiltrating lymphocytesPD-L1 in small bowel adenocarcinoma MSI-HSmall bowel adenocarcinoma expression microsatellite instability biomarkersAgedRetrospective Studiesbusiness.industryTumor-infiltrating lymphocytesbiomarkersCancerCorrectionMicrosatellite instabilitymedicine.diseaseCeliac Disease030104 developmental biologybiology.proteinEtiologyMORPHOLOGYbusiness
researchProduct

Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammator…

2019

BACKGROUND Disease phenotype and outcome of late-onset Crohn's disease are still poorly defined. METHODS In this Italian nationwide multicentre retrospective study, patients diagnosed ≥65 years (late-onset) were compared with young adult-onset with 16-39 years and adult-onset Crohn's disease 40-64 years. Data were collected for 3 years following diagnosis. RESULTS A total of 631 patients (late-onset 153, adult-onset 161, young adult-onset 317) were included. Colonic disease was more frequent in late-onset (P < 0005), stenosing behaviour was more frequent than in adult-onset (P < 0003), but fistulising disease was uncommon. Surgery rates were not different between the three age groups. Syste…

MaleDiseaseConstriction PathologictumoursInflammatory bowel diseaseLate Onset DisordersCohort Studiessurgery0302 clinical medicineCrohn DiseaseLate Onset DisordersMedicineYoung adultDigestive System Surgical ProceduresCrohn's diseaseGastroenterologyIleitisMiddle AgedColitisItaly030220 oncology & carcinogenesisoutcome030211 gastroenterology & hepatologyFemaleColorectal NeoplasmsCohort studysteroidsAdultmedicine.medical_specialtyAdolescentcomorbiditieselderly03 medical and health sciencesYoung AdultInternal medicineIntestinal FistulaHumansImmunologic FactorsGlucocorticoidsAgedRetrospective StudiesPolypharmacyHepatologybusiness.industrythiopurinesRetrospective cohort studymedicine.diseasecomorbidities; elderly; outcome; steroids; surgery; thiopurines; tumoursPolypharmacyTumor Necrosis Factor Inhibitorsbusiness
researchProduct

Health-Related Quality of Life in Italian Patients With Moderate and Severe Crohn's Disease: Interim Results from the Sole Study

2014

Health related quality of lifePediatricsmedicine.medical_specialtyCrohn's diseasebusiness.industryInterimHealth PolicymedicinePublic Health Environmental and Occupational Healthbusinessmedicine.diseaseValue in Health
researchProduct

Letter of Reply to “Response to: COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinant…

2021

To the Editors, We thank Drs. R. Mungmunpuntipantip and V. Wiwanitkit1 for their comment on our recently published article, “COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinants in a National Survey of the Italian IBD Patients’ Association”.

medicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)business.industrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)WillingneGastroenterologyMEDLINEHesitancyInflammatory Bowel DiseasesInflammatory Bowel DiseasesVaccinationInternal medicineImmunology and AllergyMedicineIn patientbusinessInflammatory Bowel Diseases
researchProduct

A Health Technology-Related Cost Description Concerning Italian Ibd Centres Dealing With Crohn's Disease Results From Sole Study

2014

medicine.medical_specialtyCrohn's diseasebusiness.industryFamily medicineHealth PolicymedicinePhysical therapyPublic Health Environmental and Occupational HealthHealth technologybusinessmedicine.diseaseValue in Health
researchProduct

Prognostic Role of Mismatch Repair Status, Histotype and High-Risk Pathologic Features in Stage II Small Bowel Adenocarcinomas

2020

Abstract Background Small bowel adenocarcinoma is a relatively rare cancer, often diagnosed in an advanced stage. In localized and resectable disease, surgery alone or in combination with adjuvant chemotherapy is the mainstay of treatment. In the recently published National Comprehensive Cancer Network Clinical Practice guidelines, criteria for selecting patients with stage II small bowel adenocarcinoma to receive adjuvant chemotherapy are provided, and they are mainly extrapolated from studies on colorectal cancer. Patients and Methods In the present study, we aimed to verify whether mismatch repair deficiency phenotype, high-risk pathologic features (including T4, positive resection margi…

MaleOncologyColorectal cancerDNA Mismatch RepairCOLORECTAL-CANCERSettore MED/120302 clinical medicinePMS2small bowel adenocarcinomaMismatch Repair Endonuclease PMS20303 health sciencesPrognosisMMRMutS Homolog 2 ProteinOncologyCARCINOMAS030220 oncology & carcinogenesisimmunohistochemistryMismatch Repair Status small bowel adenocarcinomaFemaleMicrosatellite InstabilityDNA mismatch repairMutL Protein Homolog 1Colorectal Neoplasmsstage IImedicine.medical_specialtyhigh-risk pathologic featuresDNA Mismatch Repair; Female; Humans; Male; Microsatellite Instability; Mismatch Repair Endonuclease PMS2; MutL Protein Homolog 1; MutS Homolog 2 Protein; Prognosis; Adenocarcinoma; Colorectal Neoplasmssmall bowel adenocarcinoma; mismatch repair statusAdenocarcinomaNO03 medical and health sciencessmall bowel carcinomahistotypeInternal medicineTranslational ResearchmedicineHumansmismatch repair status030304 developmental biologysmall bowel adenocarcinomasbusiness.industryCancerMicrosatellite instabilityMismatch Repair ProteinAdenocarcinoma IBD Cancermedicine.diseasedigestive system diseasesMSH6COLORECTAL-CANCER; CARCINOMAS; CONSENSUSsmall bowel carcinoma MMR immunohistochemistryMismatch repair Small bowel AdenocarcinomaMSH2Mismatch repair status; stage II; small bowel adenocarcinomas; histotype; high-risk pathologic featuresSurgeryCONSENSUSbusiness
researchProduct

COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinants in a National Survey of the Ita…

2021

The coronavirus disease 2019 (COVID-19) pandemic has not finished yet, and the most promising option towards its ending is widespread vaccination. Because patients with inflammatory bowel diseases (IBDs), namely Crohn’s disease (CD) and ulcerative colitis (UC), often require immune-modifying treatment, which might increase the risk of opportunistic infection,1 their vaccination history for several infectious diseases is routinely checked, and when inadequate, vaccination is performed at diagnosis or ideally before immune suppressive treatment is started.1 However, IBD patients were not found to be at an increased risk of developing COVID-19 or of experiencing a more severe disease course.2

medicine.medical_specialty2019-20 coronavirus outbreakCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)IBDBrief Report - ClinicalInternal medicinemedicineHumansImmunology and AllergyIn patientAcademicSubjects/MED00260SARS-CoV-2business.industryVaccinationGastroenterologyCOVID-19Inflammatory Bowel DiseasesInflammatory Bowel DiseasesCOVID-19 Vaccines HumanVaccinationIBD Crohn Ulcerative Colitis Vaccination Covid 19 Sars-Cov 2COVID-19; COVID-19 vaccine; IBD; vaccine hesitancyvaccine hesitancybusinessCOVID-19 vaccineInflammatory Bowel Diseases
researchProduct

P611 Outcome in ulcerative colitis after switch from subcutaneous anti-TNF to intravenous anti-TNF: A multicentre study

2018

medicine.medical_specialtybusiness.industryInternal medicineGastroenterologyMedicineTumor necrosis factor alphaGeneral Medicinebusinessmedicine.diseaseUlcerative colitisGastroenterologyJournal of Crohn's and Colitis
researchProduct

P463 COVID-19 vaccination willingness and hesitancy in patients with Inflammatory Bowel Diseases (IBD): analysis of determinants in a national survey…

2021

Abstract Background Vaccine hesitancy, the delay in acceptance or refusal of vaccination despite its availability, represents a threat to the diffusion and lethality of infectious diseases. COVID-19 vaccination has been recommended by national and international organizations in patients with Inflammatory Bowel Diseases (IBD). The aim of the study was to evaluate COVID-19 vaccine willingness and hesitancy in a population of Italian patients with IBD, and their determinants. Methods In February 2021 an online questionnaire focused on COVID-19 vaccine was proposed to a representative sample of Italian IBD patients. Socio-demographic characteristics, IBD features, lifestyle, perception of COVID…

2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)business.industryGastroenterologyInflammatory Bowel DiseasesGeneral MedicineClinical: Therapy and Observationmedicine.diseaseInflammatory bowel diseasePoster presentationsVaccinationVaccination RefusalFamily medicineMedicineIn patientAdverse effectbusinessAcademicSubjects/MED00260Journal of Crohn's & Colitis
researchProduct

sj-pdf-1-ueg-10.1177_2050640620964132 - Supplemental material for Activities related to inflammatory bowel disease management during and after the co…

2020

Supplemental material, sj-pdf-1-ueg-10.1177_2050640620964132 for Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care by Simone Saibeni, Ludovica Scucchi, Gabriele Dragoni, Cristina Bezzio, Agnese Miranda, Davide Giuseppe Ribaldone, Angela Bertani, Fabrizio Bossa, Mariangela Allocca, Andrea Buda, Gianmarco Mocci, Alessandra Soriano, Silvia Mazzuoli, Lorenzo Bertani, Flavia Baccini, Erika Loddo, Antonino Carlo Privitera, Alessandro Sartini, Angelo Viscido, Laurino Grossi, Valentina Casini, Viviana Gerardi, Marta Ascolani, Mirko Di Ruscio, Giovanni Casella, Edoardo Savarino, Davide Strade…

FOS: Clinical medicineFOS: Biological sciences111199 Nutrition and Dietetics not elsewhere classifiedFOS: Health sciences110308 Geriatrics and Gerontology69999 Biological Sciences not elsewhere classified111299 Oncology and Carcinogenesis not elsewhere classified
researchProduct

sj-pdf-1-ueg-10.1177_2050640620964132 - Supplemental material for Activities related to inflammatory bowel disease management during and after the co…

2020

Supplemental material, sj-pdf-1-ueg-10.1177_2050640620964132 for Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care by Simone Saibeni, Ludovica Scucchi, Gabriele Dragoni, Cristina Bezzio, Agnese Miranda, Davide Giuseppe Ribaldone, Angela Bertani, Fabrizio Bossa, Mariangela Allocca, Andrea Buda, Gianmarco Mocci, Alessandra Soriano, Silvia Mazzuoli, Lorenzo Bertani, Flavia Baccini, Erika Loddo, Antonino Carlo Privitera, Alessandro Sartini, Angelo Viscido, Laurino Grossi, Valentina Casini, Viviana Gerardi, Marta Ascolani, Mirko Di Ruscio, Giovanni Casella, Edoardo Savarino, Davide Strade…

FOS: Clinical medicineFOS: Biological sciences111199 Nutrition and Dietetics not elsewhere classifiedFOS: Health sciences110308 Geriatrics and Gerontology69999 Biological Sciences not elsewhere classified111299 Oncology and Carcinogenesis not elsewhere classified
researchProduct